This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Ketamine Administered Intravenously and by Sublingual Wafer

This study has been completed.
Information provided by (Responsible Party):
iX Biopharma Ltd. Identifier:
First received: June 19, 2011
Last updated: March 6, 2015
Last verified: March 2015
To determine the rate and extent of of absorption of racemic ketamine from sublingual wafer


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Open Label, Two Way Crossover Study to Evaluate the Bioavailability and Clinical Tolerability of a Novel Sublingual Wafer Formulation of Ketamine in Healthy Male Volunteers

Resource links provided by NLM:

Further study details as provided by iX Biopharma Ltd.:

Primary Outcome Measures:
  • Bioavailability of a single 25 mg dose of sublingual (SL) ketamine [ Time Frame: 24 hours post-dose for two dosing periods, which were separated by 7 days. ]
    Bioavailability determined by evaluation and comparison of PK variables following SL and IV administration.

Secondary Outcome Measures:
  • General clinical tolerability and safety [ Time Frame: 24 hours post-dose for two dosing periods, which were separated by 7 days. ]
    Determined by using a range of objective and subjective parameters.

  • Rate of disintegration [ Time Frame: 5 minutes post-dose ]
    Measured the apparent rate of disintegration of a single 25 mg sublingual wafer formulation of ketamine.

Biospecimen Retention:   Samples With DNA
Whole blood will be drawn into Vacuette brand, lithium heparin separator tubes (green/yellow top).

Enrollment: 8
Study Start Date: June 2011
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Detailed Description:
  1. To determine the apparent rate of disintegration of the sublingual wafer
  2. To determine the overall clinical tolerability of ketamine when administered as a single dose via the sublingual route. Tolerability will be assessed using a range of objective and subjective parameters as assessed using modified Likert and Bond and Lader scales.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
8 Healthy Male Volunteers

Inclusion Criteria:

  1. Adult males aged 18-65 years.
  2. Good general health without clinically significant renal, hepatic, cardiac or respiratory disease, as determined by the Principal Investigator.
  3. Good general mental health as determined by scores on the Symptom Checklist-90-R (SCL-90-R®), a screening instrument which evaluates a broad range of psychological problems and symptoms of psychopathology.
  4. Agree to and be capable of signing an Informed Consent Form.
  5. Have suitable venous access for blood sampling.
  6. BMI within the range of 19-30 kg/m2.

Exclusion Criteria:

  1. Renal impairment as evidenced by estimated creatinine clearance (CrCl), measured by the Cockcroft-Gault method, of less than 90 mL/min.
  2. Have a laboratory value at the Screening Visit that is outside the normal range, unless it is judged by the Investigator as not clinically significant after appropriate evaluation.
  3. A score of more than two standard deviations from the mean on any of the key nine scales in the SCL-90-R ®
  4. Any medical condition that in the opinion of the Investigator may adversely impact on the participant's ability to complete the study, including but not limited to:

    • History of cerebral trauma or stroke
    • History of seizure or epilepsy
    • Hyperthyroidism
    • Recent clinically significant URTI (within two weeks of Day 1) or respiratory infection
    • History of Myocardial Infarction or clinically significant cardiac disease including cardiac arrhythmia.
    • Poorly controlled hypertension - as assessed by the Principal Investigator.
    • Clinically significant history of asthma requiring regular supportive or preventative therapy (childhood asthma that has resolved >5 years previously may be suitable for inclusion at the discretion of the Investigator.
    • Glaucoma
  5. Plasma AST, ALT and ALP tests in excess of 1.5 times the upper limit of normal.
  6. History of severe allergic or anaphylactic drug-related reactions.
  7. History of hypersensitivity to ketamine or any of its excipients.
  8. Current (within the last six months) clinically significant psychiatric disorder including anxiety, psychosis or depression.
  9. Concurrent use of other medication on a regular or daily basis including but not limited to, theophylline, benzodiazepines, thyroxine, sedatives or anti-anxiolytics.
  10. Participation in another clinical trial of an investigational agent within 30 days of study entry.
  11. Known history of past or present infection with hepatitis C virus (HCV), hepatitis B or human immunodeficiency virus (HIV).
  12. Clinically significant abnormal ECG (12-lead) at the screening visit or prior to dosing on Day 1, as determined by the Investigator.
  13. Participants who have a marked prolongation of the QT corrected (QTc) interval (i.e., repeated demonstration of a QTc >430 msec for males) at screening or prior to dosing on Day 1 in either study period will not be allowed to continue in the study.
  14. Significant history of illicit drug or alcohol use or abuse (as determined by the Principal Investigator).
  15. Any alcohol use within 24 hours prior to dosing on Day 1 in each of the study periods.
  16. Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant returning for follow-up visits on schedule.
  17. Blood donation (1 unit or more) within 1 month prior to the screening visit.
  18. Current or previous tobacco user (within 12 months prior to Day 1) .
  19. Planned surgical procedure requiring general anaesthesia during the study period and within two weeks of study completion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01377831

Australia, South Australia
Pain and Anaesthesia Research Clinic (PARC), Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Sponsors and Collaborators
iX Biopharma Ltd.
Principal Investigator: Pual Rolan Pain and Anaesthesia Research Clinic - PARC
  More Information

Responsible Party: iX Biopharma Ltd. Identifier: NCT01377831     History of Changes
Other Study ID Numbers: KET001
Study First Received: June 19, 2011
Last Updated: March 6, 2015

Additional relevant MeSH terms:
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 22, 2017